Stabilis

Vasopressin

Noms commerciaux

Pressyn	Canada

Compatibilités

		Vasopressin : 0.2 UI/ml Amiodarone hydrochloride : 6 mg/ml	0.45 2.5	1611
		Vasopressin : 2 & 4 UI/ml Amiodarone hydrochloride : 1.5 mg/ml		1801
		Vasopressin : 0.4 UI/ml Argatroban : 1 mg/ml		1963
		Vasopressin : 1 UI/ml Calcium chloride : 20 mg/ml		4732
		Vasopressin : 0.2 UI/ml Caspofungin acetate : 0.5 mg/ml		2017
		Vasopressin : 1 UI/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Vasopressin : 1 UI/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Vasopressin : 1 UI/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Vasopressin : 1 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Vasopressin : 1 UI/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Vasopressin : 1 UI/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Vasopressin : 0.2 UI/ml Ciprofloxacin lactate : 2 mg/ml		2017
		Vasopressin : 1 UI/ml Cisatracurium besylate : 1 mg/ml		3429
		Vasopressin : 2 & 4 UI/ml Diltiazem hydrochloride : 1 mg/ml		1801
		Vasopressin : 2 & 4 UI/ml Dobutamine hydrochloride : 4.2 mg/ml		1801
		Vasopressin : 0.2 UI/ml Dopamine hydrochloride : 3.2 mg/ml		2017
		Vasopressin : 2 & 4 UI/ml Dopamine hydrochloride : 4.2 mg/ml		1801

	✓	Vasopressin : 2 & 4 UI/ml Epinephrine hydrochloride : 4 µg/ml	▲	1801
	✓	Vasopressin : 1 UI/ml Eravacycline : 0,6 mg/ml	▲	4434
	✓	Vasopressin : 0.2 UI/ml Fluconazole : 2 mg/ml	▲	2017
	✓	Vasopressin : 1 UI/ml Fosfomycin : 30 mg/ml	▲♦	4055
	✓	Vasopressin : 1 UI/ml Furosemide : 10 mg/ml	∅	3210
	✓	Vasopressin : 1 UI/ml Furosemide : 10 mg/ml	▲	4570
	✓	Vasopressin : 1 UI/ml Furosemide : 1 mg/ml	▲	4570
↓	✓	Vasopressin : 0.4 UI/ml Furosemide : 4 mg/ml	▲♦	2116
	✓	Vasopressin : 0.2 UI/ml Gentamicin sulfate : 1.2 mg/ml	▲	2017
	✓	Vasopressin : 2 & 4 UI/ml Heparin sodium : 100 UI/ml	▲	1801
	✓	Vasopressin : 0.2 UI/ml Imipenem - cilastatin sodium : 5/5 mg/ml	▲	2017
	✓	Vasopressin : 1 UI/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml	▲♦	4433
	✓	Vasopressin : 0.2 UI/ml Insulin : 1 UI/ml	▲	2017
	✓	Vasopressin : 0,5 & 1 UI/ml Insulin aspart : 1 UI/ml	▲♦	1508
	✓	Vasopressin : 1 UI/ml Isavuconazonium sulfate : 1.5 mg/ml	▲♦	3829
	✓	Vasopressin : 20 UI/ml Ketamine hydrochloride : 50 mg/ml		4389
	✓	Vasopressin : 1 UI/ml Levetiracetam : 5 mg/ml	▲	4569
	✓	Vasopressin : 2 & 4 UI/ml Lidocaine hydrochloride : 4 mg/ml	▲	1801
	✓	Vasopressin : 0.2 UI/ml Linezolid : 2 mg/ml	▲	2017
	✓	Vasopressin : 0.2 UI/ml Meropenem : 5 mg/ml	▲	2017
	✓	Vasopressin : 0.2 UI/ml Metronidazole : 5 mg/ml	▲	2017
	✓	Vasopressin : 1 UI/ml Micafungin : 1.5 mg/ml	▲	2108
	✓	Vasopressin : 2 & 4 UI/ml Milrinone lactate : 0.2 mg/ml	▲	1801
	✓	Vasopressin : 0.2 UI/ml Moxifloxacin : 1.6 mg/ml	▲	2017
	✓	Vasopressin : 2 & 4 UI/ml Nitroglycerin : 0.2 mg/ml	▲	1801
	✓	Vasopressin : 0.2 UI/ml Norepinephrine bitartrate : 0.004 & 0.016 mg/ml	▲	2017

		Vasopressin : 2 & 4 UI/ml Norepinephrine bitartrate : 0.004 mg/ml		1801
		Vasopressin : 0.4 >> 1 UI/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
		Vasopressin : 2 & 4 UI/ml Phenylephrine hydrochloride : 0.04 mg/ml		1801
		Vasopressin : 0.2 UI/ml Phenytoin sodium : 50 mg/ml		2017
		Vasopressin : 0.2 UI/ml Piperacillin sodium / tazobactam : 112.5 mg/ml		2017
		Vasopressin : 1 UI/ml Plazomicin sulfate : 24 mg/ml		4145
		Vasopressin : 2 & 4 UI/ml Procainamide hydrochloride : 4 mg/ml		1801
		Vasopressin : 0.2 UI/ml Sodium bicarbonate : 12.6 mg/ml		2017
		Vasopressin : 1 UI/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Vasopressin : 1 UI/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Vasopressin : 1 UI/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Vasopressin : 0.04 UI/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Vasopressin : 0.2 UI/ml Voriconazole : 3 mg/ml		2017
		Vasopressin : 0,2 UI/ml	Normo Sol®	4655

Voie d'administration

Bibliographie

	Type	Source
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.

1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1963	Revue	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2116	Revue	Faria CE, Fiumara K, Patel N, Tran DC. Visual compatibility of furosemide with phenylephrine and vasopressine. Am J Health-Syst Pharm 2006 ; 63: 906-908.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3429	Revue	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.

4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4569	Revue	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4570	Revue	Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019
4655	Revue	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4732	Revue	Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3;164–170

Dictionnaire

	Hormone		Injectable
	Noms commerciaux		Compatibilités
	Molécule		Solvant
	Bibliographie		Compatible
	NaCl 0,45% Glucose 2,5%		Chlorure de sodium 0,9%
	Glucose 5%		NaCl 0,9% ou glucose 5%
RL	Ringer lactate	Ø	Aucun
	Précipitation immédiate		Incompatible
Normo Sol®	Normosol®		Voie d'administration
	Intraveineuse		Intramusculaire
	Sous cutanée		Bibliographie
	Dictionnaire		